MARKET

INO

INO

Inovio Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.14
+0.39
+5.03%
After Hours: 8.10 -0.04 -0.49% 19:44 09/17 EDT
OPEN
7.80
PREV CLOSE
7.75
HIGH
8.15
LOW
7.68
VOLUME
6.42M
TURNOVER
--
52 WEEK HIGH
19.00
52 WEEK LOW
5.81
MARKET CAP
1.71B
P/E (TTM)
-11.7937
1D
5D
1M
3M
1Y
5Y
Looking Into Inovio Pharmaceuticals's Return On Capital Employed
Inovio Pharmaceuticals (NASDAQ:INO) brought in sales totaling $272.82 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 58.32%, resulting in a loss of $83.20 million.
Benzinga · 1d ago
Is Inovio Stock A Buy After Brazil OKs Phase 3 Test For Covid Vaccine?
Is INO stock a buy after Brazil's national health agency granted Inovio permission to begin a Phase 2 and Phase 3 Covid vaccine test?
Investor's Business Daily · 2d ago
Inovio Downgraded by BofA on Limited Covid Opportunity
Company's COVID vaccine candidate has lower likely returns than other therapies with longer timelines, BofA said.
TheStreet.com · 09/10 18:42
B of A Securities Downgrades Inovio Pharmaceuticals to Underperform, Lowers Price Target to $8
B of A Securities analyst Geoff Meacham downgrades Inovio Pharmaceuticals (NASDAQ:INO) from Neutral to Underperform and lowers the price target from $9 to $8.
Benzinga · 09/10 15:58
--BofA Securities Downgrades Inovio Pharmaceuticals to Underperform From Neutral, Sets $8 Price Target
MT Newswires · 09/10 10:03
U.S. inoculates 75% of adults with at least one dose of COVID-19 vaccine
According to the White House, three-quarters of adults in the U.S. have received at least one dose of a COVID-19 vaccine as of Tuesday - Bloomberg. White House COVID-19 data
Seekingalpha · 09/08 09:23
Inovio Pharmaceuticals Inc. stock falls Friday, underperforms market
marketwatch.com · 09/03 21:00
Moderna vs. Inovio Pharmaceuticals: Which Coronavirus Vaccine Stock is a Better Investment?
StockNews.com · 09/03 16:46
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INO. Analyze the recent business situations of Inovio Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INO stock price target is 13.22 with a high estimate of 35.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 326
Institutional Holdings: 76.31M
% Owned: 36.28%
Shares Outstanding: 210.36M
TypeInstitutionsShares
Increased
67
9.06M
New
40
1.03M
Decreased
46
1.69M
Sold Out
45
9.41M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Simon Benito
Chief Executive Officer/President/Director
Jong Kim
Non-Executive Vice Chairman/Independent Director
Jay Shepard
Chief Financial Officer
Peter Kies
Chief Operating Officer
Jacqueline Shea
Chief Scientific Officer
Laurent Humeau
Director
Roger Dansey
Director
David Weiner
Independent Director
Ann Miller
Independent Director
Wendy Yarno
Independent Director
Lota Zoth
No Data
About INO
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Webull offers kinds of Inovio Pharmaceuticals Inc stock information, including NASDAQ:INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INO stock methods without spending real money on the virtual paper trading platform.